On June 11, 2025, HC Wainwright & Co. analyst Douglas Tsao reiterated a "Buy" rating for Cabaletta Bio (CABA, Financial). This action by Tsao ensures continued confidence in the company’s market performance.
The price target (PT) for Cabaletta Bio remains at $25.00 USD, as previously set by HC Wainwright & Co., indicating no change in their valuation perspective. This maintained price target suggests stable expectations for CABA's future stock performance.
Cabaletta Bio, listed under the ticker CABA on NASDAQ, has consistently been rated as "Buy" by HC Wainwright & Co., reflecting positive sentiment from the analyst community regarding the company's growth potential. Investors should note that no percentage change in the price target was reported in this update.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Cabaletta Bio Inc (CABA, Financial) is $15.89 with a high estimate of $28.00 and a low estimate of $3.00. The average target implies an upside of 807.94% from the current price of $1.75. More detailed estimate data can be found on the Cabaletta Bio Inc (CABA) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Cabaletta Bio Inc's (CABA, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
